Progress in the research of P-gp inhibitors

Abstract

Abstract: Multidrug resistance (MDR) is one of the major obstacles to cancer chemotherapy. It is now well established that MDR phenotype is strongly correlated with the over-expression of P-glycoprotein (P-gp), a membrane glycoprotein encoded by MDR1 gene. There is very great progress in the research of the P-gp inhibitors in recent years. This article describes the current research state of the P-gp inhibitors.

Key words: tumor, multidrug resistance, P-glycoprotein inhibitor, phenotype

CLC Number:

R963

ZHANG Yu. Progress in the research of P-gp inhibitors[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(10): 1087-1090.

References

1 Gottesman MM, Fojo T, Bates SE.Multidrug resistance in cancer: role of ATP-dependent transporters[J]. Nat Rev Cancer, 2002; 2(1): 48-58
2 Dean M, Rzhetsky A, Allikmets R.The human ATP-binding cassette (ABC ) transporter superfamily [J]. Genome Res, 2001;11(7): 1156-66
3 Shoshani T, Zhang S, Dey S, Pastan I, GottesmanMM.Analysis of random recombination between human MDR1 and Mouse MDR1a cDNA in a pHMDR-Dihydrofolate reductase bicistronic expression system[J]. Mol Pharmacol, 1998; 54(4): 623-30
4 Loo TW, Bartlett MC, Clarke DM. Drug binding in human Pglycoprotein causes conformational changes in both nucleotidebinding domains[J]. J Biol Chem 2003;278(50): 1575-8
5 Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter[J]. Annu Rev Biochem, 1993; 62(10): 385-427
6 Witherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, Wissel PS. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918[J]. Clin Cancer Res, 1996; 2(1): 7-12
7 Ernest S, Bello-Reuss E.Expression and function of P-gly coprotein in a mouse kiney cell line[J]. Am J Physiol, 1995; 269 (2 Pt 1): C323-33
8 Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A.Active secretion of drug form the intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier[J]. J Pharm Pharmacol, 1996;48(10): 1083-9
9 Roman RM, Wang Y, Lidofsky SD, Feranchak AP, Lomri N, Scharschmidt BF, et al. Hepatocellular ATP-binding cassette protein expression enhances ATP release and autocrine regulation of cell volume[J]. J Biol Chem, 1997;272(35): 1970-6
10 Wu J, Zhang JJ, Koppel H, Jacob TJ.P-gly coprotein regulates a volume-actived chloride current in bovine non-pigmented ciliary epithelial cells[J]. J Physcol, 1996;491(Pt3): 743-55
11 Borst P, Zelcer N, van Helvoort A.ABC transporters in lipid transport[J]. Biochem Biophys Acta, 2000;1486(1): 128-44
12 Bello-Reuss E, Ernest S, Holland OB, Hellmich MR.Role of multidrug resistance P-gly coprotein in the secretion of aldosterone by human adrenal NCI-H295 cells[J]. Am J Phy siol Cell Physiol, 2000;278(6): C1256-65
13 Fardel O, Lecureur V, Guillouzo A.The P-glycoprotein multidrug transporter[J]. Gen Pharmcol, 1996;27(8): 1283-91
14 Ambudkar SV, Dey S, Hry cyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter[J]. Annu Rev Pharmacol Toxicol, 1999;39(4): 361-98
15 Krishna R, Mayer LD.Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer srug[J]. Eur J Pharm Sci, 2000;11(4): 265-83
16 Te Boekhorst PA, Van KJ, Schoester M, Sonneveld P.Reversal of typical multidrug resistance by cyclosporin and its non-immunosupressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype[J]. Cancer Chemother Pharmcol, 1992;30(3): 238-42
17 Coley HM, Verrill MW, Gregson SE.Inciduce of P-glycoprotien over expression and mutidrug resistance(MDR) reversal in adult soft tissue sarcoma[J]. Eur J Cancer, 2000;36(7): 881-8
18 Minami H, Ohtsu T, Fujii H, Igarashi T, Itoh K, Uchiyama-Kokubu N, et al. Phase Ⅰ study of Intravenous PSC-833 and doxorubicin: Reversal of multidrug resistance[J]. Jpn J Cancer Res, 2001; 92(2): 220-30
19 Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, LitchmanM, A phase Ⅰ trial of doxorubicin, and paclitaxel, and valspodar(PSC833), a modulator of multidrug resistance[J]. Clin Cancer Res, 2001; 7(5): 1221-9
20 Baekelandt M, Lehne G, Trope CG, Szanto I, Pfeiffer P, Gustavssson B, et al. Phase Ⅰ Ⅱ trial of the multidrug-resistance modulator valspodar combined ith cisplatin and doxorubicin in refractory ocarian cancer[J]. J Clin Oncol, 2001;19 (12): 2983-93
21 Baekelandt M, Lehne G, Trope CG, Szanto I, Pfeiffer P, Gustavssson B, et al. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-gly coprotein-mediated multidrug resistance in vitro [J]. Anticancer Drugs, 1997; 8(2): 125-40
22 Pritchard-Jones K.BIRICODIA(VX-710; Incel): an effective chemosensitizer in neuroblastoma[J]. Br J Cancer, 1999;80 (8): 1190-6
23 Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, et al. A phase Ⅱ study of MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy[J]. Gynecol Oncol, 2002;86(3): 302-10
24 Rago RP, Einstein A Jr, Lush R, Beer TM, Ko YJ, Henner WD, et al. Safety and efficacy of the MDR inhibitor Incel(biricodar, VX-710 ) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer[J]. Cancer Chemother Pharmacol, 2003;51(4): 297-305
25 Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, et al. Safety and efficacy of the multidrug resistance inhibitor Incel(biricodar; VX-710) in combination with mitoxantrone for advanced breast cancer refractory to paclitaxel[J]. Clin Cancer Res, 2002;8(3): 670-8
26 Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ. P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies[J]. Cancer Res, 1999;59 (16): 3944-8
27 Lum BL, Gosland MP.MDR expression in normal tissues: pharmacologic implications for the clinical use of P-glycoprotein inhibitor[J]. Hematol Oncol Clin North Am, 1995; 9(24 Pt 1): 319-36
28 Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, et al. In vitro and in vivo reversal of P-glycoproteinmediated multidrug resistance by a novel potent modulator, XR9576[J]. Cancer Res, 2001;61(2): 749-58
29 Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P.A phase Ⅰ study trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56 +lymphocytes after oral and intravenous administration[J]. Clin Cancer Res, 2000;6(11): 4186-91
30 Thomas H, Coley HM. Overcoming multidrug resistance in Cancer: An update on the clinical strategy of inhibiting P-glycoprotein[J]. Cancer control, 2003;10(2): 159-65
31 Goldman B. Multidrug resistance: Can new drugs help chemotherapy score against cancer[J]. JNCI, 2003; 95(4): 255-7
32 NewmanMJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-medited multidrug resistance[J]. Cancer Res, 2000; 60(11): 2964-72

[1]	LI Yanyang, WANG Yunjiao, LV Shichao. Effects and mechanism of traditional Chinese medicine injection in prevention and treatment of cardiotoxicity induced by antineoplastic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 572-577.
[2]	LI Ruoning, GUO Zhanli, WANG Yuan, SUN Jianjun. Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 438-444.
[3]	WANG Siyu, LI Jiawei, LI Chenghao, LI Ling, GUO Qingyang, QIU Lu, ZHOU Shiqin, LIU Yongqi. Research progress of lactate dehydrogenase A in digestive system tumors and related drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 445-454.
[4]	LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
[5]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[6]	ZHANG Wei, WANG Hongyuan, LEI Xiaohang, ZHAO Yingshuai, LV Weichao, ZHANG Jianguo. BCG + piroxicam versus BCG + gemcitabine for prevention of postoperative recurrence in intermediate- and high-risk bladder cancer and effects on serum AGR and PON1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1146-1153.
[7]	LIU Dan, LIU Ming, JIN Liangyou, PAN Juan, XIN Haoru, LIU Mengyuan, LI Xin, ZHENG Kun, FENG Xiaoling. Research progress on the antitumor activity of costunolide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1168-1176.
[8]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[9]	HUANG Hao, JIA Hong, WANG Xiaoshuang, ZHANG Lu, JIANG Hua. Effects of co-culture of dendritic cells loaded with MAGE-A3 antigen and cytokine-induced killer cells on tumor stem cells and malignant progression of endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 42-50.
[10]	GAO Lili, WANG Yuzhu, WANG Yan, LI Jian, WANG Jun. General considerations for clinical pharmacology of antitumor antibody-conjugated drugs: Implications from FDA review cases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 75-85.
[11]	LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
[12]	HONG Ziqiang, GOU Wenxi, CUI Baiqiang, BAI Xiangdou, JIN Dacheng, GOU Yunjiu. Role of the m7G methyltransferase METTL1 in tumours [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 93-100.
[13]	WANG Yali, HUO Xulei, CHEN Feng, LI Shenglan, ZHENG Xiaohong, WANG Can, LI Wenbin. Research progress on the antitumor effect of nifurtimox [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 955-960.
[14]	SHI Jingbin, XIONG Yang. Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.
[15]	MA Wangbo, Ma Yue, FAN Fangtian, ZHANG Yuhan, CHANG Jingwen, ZHOU Zhihua. Effects of Shenqi fuzheng injection on low-glucose-mediated immunosuppressive microenvironment and its mechanism of action [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 136-143.